Evidence map›Paper›PMID 37771782›Full record

ArticleTheranostics2023

Oral [60]fullerene reduces neuroinflammation to alleviate Parkinson's disease via regulating gut microbiome.

Xue Li, Ruijun Deng, Jie Li, Hui Li, Zhe Xu, Lei Zhang, Linyin Feng, Chunying Shu, Mingming Zhen, Chunru Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Study of fullerene CScientific reports · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Distinctive Effects of Fullerene CAntioxidants (Basel, Switzerland) · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Xue LiBeijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
Ruijun DengBeijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
Jie LiBeijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
Hui LiBeijing Fullcan Biotechnology Co., Ltd., Beijing, 100085, China.
Zhe XuChifeng Fullcan Biotechnology Co., Ltd., Inner Mongolia, 024099, China.
Lei ZhangUniversity of Chinese Academy of Sciences, Beijing 100049, China.
Linyin FengUniversity of Chinese Academy of Sciences, Beijing 100049, China.
Chunying ShuBeijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
Mingming ZhenBeijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
Chunru WangBeijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
Chinese Academy of Sciences · CNBeijing VDJBio (China) · CNChifeng University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroinflammation is considered to drive the pathogenic process of neuronal degeneration in Parkinson's disease (PD). However, effective anti-neuroinflammation therapeutics for PD still remain dissatisfactory. Here we explore a robust therapeutic strategy for PD using anti-neuroinflammatory fullerenes.

Indexed as

FullerenesGastrointestinal MicrobiomeNeuroinflammatory DiseasesParkinson Disease1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAdministration, OralAnimalsDisease Models, AnimalMaleMiceMice, Inbred C57BLRNA, Ribosomal, 16S1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridinefullerene C60FullerenesRNA, Ribosomal, 16SGut microbiotaNeurodegenerationNeuroinflammationOral fullereneParkinson's disease

Identifiers

PMID37771782
PMCPMC10526674
OpenAlexW4387110448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.